Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

•   Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry (Articolo in rivista) (literal)

Anno

• 2010-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.2217/pgs.09.172 (literal)

Alternative label

• Falzoi M; Mossa A; Congeddu E; Saba L; Pani L. (2010)
    Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry
  in Pharmacogenomics (Lond.)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Falzoi M; Mossa A; Congeddu E; Saba L; Pani L. (literal)

Pagina inizio

• 559 (literal)

Pagina fine

• 571 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 11(4) (literal)

Rivista

• Pharmacogenomics (Rivista)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Istituto Tecnologie Biomediche del Consiglio Nazionale delle Ricerche CNR-ITB, Parco Scientifico e Tecnologico della Sardegna, Ed. 5, Loc. Piscinamanna, 09010 Pula (CA) Italy. (literal)

Titolo

•   Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry (literal)

Abstract

• Pharmacogenetics is the study of genetic variations that cause alterations in drug level, drug response and adverse drug reactions. SNPs found in CYP450 genes have the greatest genetic influences on interindividual variability in drug bioavailability. The polymorphic nature of these genes may modulate several enzyme levels that affect individual responses to pharmacological treatment. Among them, CYP3A4, CYP3A5, CYP2C9 and CYP2C19 isoforms of CYP450 enzymes are involved in the metabolism of many commonly prescribed drugs. Aims: In this study, we would like to develop a CYP450 genotyping platform that could lead a complete definition of a patient's metabolic genotype in order to improve the clinical outcome of some drug treatments. Materials & methods: We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Sequenom®) to develop a SNP genotyping method. Results: This MALDI-TOF-based multiplexing system allows the simultaneous and efficient genotyping of a set of CYP450 gene polymorphisms. Conclusion: The multiple CYP450 gene testing achieved with this application can be used to develop diagnostic tests to predict drug responses and clinical outcomes. (literal)

Prodotto di

• Drug design, drug delivery e valutazione preclinica di nuove entità chimiche. (ME.P06.020.001) (Modulo)

Autore CNR

• LUCA PANI (Unità di personale interno)

Incoming links:

Autore CNR di

• LUCA PANI (Unità di personale interno)

Prodotto

• Drug design, drug delivery e valutazione preclinica di nuove entità chimiche. (ME.P06.020.001) (Modulo)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Pharmacogenomics (Rivista)